BRAFV595E detection, uroplakin II expression and PAS staining for diagnosing canine urothelial carcinoma

The gold standard for diagnosing canine urothelial carcinoma (CaUC) is histopathological examination of an incisional/excisional biopsy which is an invasive technique. The risk of tumor seeding by performing invasive techniques in CaUC is known for reason to explore minimally invasive diagnostic tools. Recently, accurate urine-based screening tests, particularly for BRAFV595E detection, have emerged with promising utility. In addition, uroplakin (UPII) is a specific urothelial cell marker for immunohistochemistry (IHC) that is widely used in humans and considered superior to uroplakin III (UPIII) particularly in higher diagnostic sensitivity of poorly differentiated or metastatic carcinoma; however, its expression in CaUC has not been evaluated. This retrospective study aimed to assess UPII and Ki-67 expression in 20 CaUCs (19 urinary bladder and 1 prostate gland) using special stain and IHC. Glycoprotein accumulation in neoplastic urothelial cells was also evaluated using periodic acid–Schiff (PAS) staining to confirm the location of uroplakin plaques. Tumor proliferation was evaluated using the Ki-67 score by IHC. Additionally, BRAFV595E detection by real-time polymerase chain reaction (qPCR) was investigated in three specimen types: urinary cell pellet (UCP), fresh tumor tissue (FT), and formalin-fixed paraffin-embedded tissue (FFPE), and the suitability of these for CaUC screening was compared in 23 CaUCs and 34 controls. Overall, BRAFV595E was detected in 47.8% (11/23) of CaUCs and 2.9% (1/34) of controls. UCP and FT showed consistent BRAF genotypes (k = 0.865, p < 0.001), and heterozygous BRAF mutations were confirmed by chromatogram analysis. UPII was expressed in all CaUCs (100%, 20/20). PAS staining was positive in 86.7% of CaUC cases (13/15). Ki-67 score was not related to histological grade. No association was observed between histological grade, BRAF variant, Ki-67, and UPII expression. In conclusion, qPCR is a promising tool for BRAFV595E detection, and combined IHC for UPII with PAS staining may enhance diagnostic accuracy for CaUC.

Authors

Institutions

Publication Details

Journal
Veterinary Research Communications
Published
2026-03-31
DOI
https://doi.org/10.1007/s11259-026-11177-5
Primary Topic
Veterinary Medicine and Surgery
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

BRAFV595E detection, uroplakin II expression and PAS staining for diagnosing canine urothelial carcinoma

Somporn Techangamsuwan, Anudep Rungsipipat, Panitnan Punyathi, Sirintra Sirivisoot et al.
Veterinary Research Communications
Veterinary Medicine and Surgery
article

BRAFV595E detection, uroplakin II expression and PAS staining for diagnosing canine urothelial carcinoma

Somporn Techangamsuwan, Anudep Rungsipipat, Panitnan Punyathi, Sirintra Sirivisoot, Narisara Chimnakboon, Monticha Kitnitchee, Jesada Siripoonsub
article en

Abstract

The gold standard for diagnosing canine urothelial carcinoma (CaUC) is histopathological examination of an incisional/excisional biopsy which is an invasive technique. The risk of tumor seeding by performing invasive techniques in CaUC is known for reason to explore minimally invasive diagnostic tools. Recently, accurate urine-based screening tests, particularly for BRAFV595E detection, have emerged with promising utility. In addition, uroplakin (UPII) is a specific urothelial cell marker for immunohistochemistry (IHC) that is widely used in humans and considered superior to uroplakin III (UPIII) particularly in higher diagnostic sensitivity of poorly differentiated or metastatic carcinoma; however, its expression in CaUC has not been evaluated. This retrospective study aimed to assess UPII and Ki-67 expression in 20 CaUCs (19 urinary bladder and 1 prostate gland) using special stain and IHC. Glycoprotein accumulation in neoplastic urothelial cells was also evaluated using periodic acid–Schiff (PAS) staining to confirm the location of uroplakin plaques. Tumor proliferation was evaluated using the Ki-67 score by IHC. Additionally, BRAFV595E detection by real-time polymerase chain reaction (qPCR) was investigated in three specimen types: urinary cell pellet (UCP), fresh tumor tissue (FT), and formalin-fixed paraffin-embedded tissue (FFPE), and the suitability of these for CaUC screening was compared in 23 CaUCs and 34 controls. Overall, BRAFV595E was detected in 47.8% (11/23) of CaUCs and 2.9% (1/34) of controls. UCP and FT showed consistent BRAF genotypes (k = 0.865, p < 0.001), and heterozygous BRAF mutations were confirmed by chromatogram analysis. UPII was expressed in all CaUCs (100%, 20/20). PAS staining was positive in 86.7% of CaUC cases (13/15). Ki-67 score was not related to histological grade. No association was observed between histological grade, BRAF variant, Ki-67, and UPII expression. In conclusion, qPCR is a promising tool for BRAFV595E detection, and combined IHC for UPII with PAS staining may enhance diagnostic accuracy for CaUC.

Veterinary Research CommunicationsVol. 50(3)
Chulalongkorn University (TH)
Chulalongkorn University, Faculty of Veterinary Science, Chulalongkorn University
Openalex Percentile: Top 26%
Veterinary Medicine and Surgery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.